These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 22952344)

  • 1. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer.
    Madhavan D; Zucknick M; Wallwiener M; Cuk K; Modugno C; Scharpff M; Schott S; Heil J; Turchinovich A; Yang R; Benner A; Riethdorf S; Trumpp A; Sohn C; Pantel K; Schneeweiss A; Burwinkel B
    Clin Cancer Res; 2012 Nov; 18(21):5972-82. PubMed ID: 22952344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis.
    Madhavan D; Peng C; Wallwiener M; Zucknick M; Nees J; Schott S; Rudolph A; Riethdorf S; Trumpp A; Pantel K; Sohn C; Chang-Claude J; Schneeweiss A; Burwinkel B
    Carcinogenesis; 2016 May; 37(5):461-70. PubMed ID: 26785733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
    Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
    Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
    Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN
    Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
    Dawood S; Broglio K; Valero V; Reuben J; Handy B; Islam R; Jackson S; Hortobagyi GN; Fritsche H; Cristofanilli M
    Cancer; 2008 Nov; 113(9):2422-30. PubMed ID: 18785255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.
    Gonzales JC; Fink LM; Goodman OB; Symanowski JT; Vogelzang NJ; Ward DC
    Clin Genitourin Cancer; 2011 Sep; 9(1):39-45. PubMed ID: 21723797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment.
    Fischer C; Turchinovich A; Feisst M; Riedel F; Haßdenteufel K; Scharli P; Hartkopf AD; Brucker SY; Michel L; Burwinkel B; Schneeweiss A; Wallwiener M; Deutsch TM
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients.
    Alunni-Fabbroni M; Majunke L; Trapp EK; Tzschaschel M; Mahner S; Fasching PA; Fehm T; Schneeweiss A; Beck T; Lorenz R; Friedl TWP; Janni W; Rack B;
    BMC Cancer; 2018 Feb; 18(1):141. PubMed ID: 29409452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis.
    Madhavan D; Wallwiener M; Bents K; Zucknick M; Nees J; Schott S; Cuk K; Riethdorf S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Surowy H; Burwinkel B
    Breast Cancer Res Treat; 2014 Jul; 146(1):163-74. PubMed ID: 24838941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation among [18F]fluorodeoxyglucose positron emission tomography/computed tomography, cancer antigen 27.29, and circulating tumor cell testing in metastatic breast cancer.
    Saad A; Kanate A; Sehbai A; Marano G; Hobbs G; Abraham J
    Clin Breast Cancer; 2008 Aug; 8(4):357-61. PubMed ID: 18757264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients.
    Kumar S; Keerthana R; Pazhanimuthu A; Perumal P
    Indian J Biochem Biophys; 2013 Jun; 50(3):210-4. PubMed ID: 23898484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of tumor markers and circulating tumors cells in the management of breast cancer.
    Saad A; Abraham J
    Oncology (Williston Park); 2008 Jun; 22(7):726-31; discussion 734, 739, 743-4. PubMed ID: 18619119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis.
    Yan LX; Huang XF; Shao Q; Huang MY; Deng L; Wu QL; Zeng YX; Shao JY
    RNA; 2008 Nov; 14(11):2348-60. PubMed ID: 18812439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.
    Giordano A; Giuliano M; De Laurentiis M; Eleuteri A; Iorio F; Tagliaferri R; Hortobagyi GN; Pusztai L; De Placido S; Hess K; Cristofanilli M; Reuben JM
    Breast Cancer Res Treat; 2011 Sep; 129(2):451-8. PubMed ID: 21710134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival.
    Silva J; García V; Zaballos Á; Provencio M; Lombardía L; Almonacid L; García JM; Domínguez G; Peña C; Diaz R; Herrera M; Varela A; Bonilla F
    Eur Respir J; 2011 Mar; 37(3):617-23. PubMed ID: 20595154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct Comparison of Metastasis-Related miRNAs Expression Levels in Circulating Tumor Cells, Corresponding Plasma, and Primary Tumors of Breast Cancer Patients.
    Markou A; Zavridou M; Sourvinou I; Yousef G; Kounelis S; Malamos N; Georgoulias V; Lianidou E
    Clin Chem; 2016 Jul; 62(7):1002-11. PubMed ID: 27197674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients.
    Tokudome N; Ito Y; Takahashi S; Kobayashi K; Taira S; Tsutsumi C; Oto M; Oba M; Inoue K; Kuwayama A; Masumura K; Nakayama Y; Watanabe C; Hatake K
    Breast Cancer; 2011 Jul; 18(3):195-202. PubMed ID: 21465230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening.
    Ng EK; Chong WW; Jin H; Lam EK; Shin VY; Yu J; Poon TC; Ng SS; Sung JJ
    Gut; 2009 Oct; 58(10):1375-81. PubMed ID: 19201770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment.
    Bredemeier M; Edimiris P; Tewes M; Mach P; Aktas B; Schellbach D; Wagner J; Kimmig R; Kasimir-Bauer S
    Oncotarget; 2016 Jul; 7(27):41677-41690. PubMed ID: 27223437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients.
    Wong NS; Kahn HJ; Zhang L; Oldfield S; Yang LY; Marks A; Trudeau ME
    Breast Cancer Res Treat; 2006 Sep; 99(1):63-9. PubMed ID: 16541316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.